Ranolazine: An Antiarrhythmic and Cardioprotective Agent
Antonis A Manolis1, Theodora A Manolis2, Apostolos Vouliotis3
1From the Department of Int. Medicine, Elpis General Hospital, Athens, Greece.
Cardiology in Review
|July 17, 2026
Summary
Ranolazine effectively treats chronic angina by targeting late sodium channel activity during ischemia, improving exercise tolerance. It serves as a crucial second-line therapy when other medications are ineffective or contraindicated.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Ranolazine exhibits dual action as a metabolic modulator and membrane stabilizer.
- It is recognized for anti-ischemic and antianginal effects, with secondary benefits including antioxidant capacity and glycemic control.
Purpose of the Study:
- To review the role of ranolazine in managing stable ischemic heart disease.
- To highlight its efficacy as a second-line antianginal agent.
Main Methods:
- Review of current guidelines and medical literature on ranolazine.
- Analysis of ranolazine's mechanism of action on myocardial sodium channels during ischemia.
Main Results:
- Ranolazine increases exercise duration and time-to-ischemia in patients with stable angina.
- It is recommended as a second-line agent for chronic angina, particularly when beta-blockers are contraindicated or insufficient.
- Ranolazine offers an alternative when primary treatments cause hypotension or bradycardia, as it lacks significant vasoactive or bradycardic effects.
Conclusions:
- Ranolazine is a valuable therapeutic option for chronic angina symptom relief.
- Its unique mechanism and favorable safety profile support its use as a second-line or add-on therapy.
Related Concept Videos
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...